Business context and reporting period
This is Access Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2011—not a filing identified in the request metadata as Abeona Therapeutics Inc. Investors should verify the issuer and filing identity. Access was an emerging biopharmaceutical company with MuGard launched in the U.S. and Europe, ProLindac and Thiarabine in clinical development, and other programs at the preclinical stage.
Financial performance and position
| Metric | Three months ended September 30, 2011 | Nine months ended September 30, 2011 |
|---|---|---|
| Total revenue | $1.041 million, versus $127,000 | $1.342 million, versus $334,000 |
| Operating expenses | $2.825 million, versus $2.423 million | $7.528 million, versus $6.213 million |
| Loss from operations | $1.784 million, versus $2.296 million | $6.186 million, versus $5.879 million |
| Net income (loss) | $350,000, versus a $12.719 million loss | $2.813 million loss, versus a $9.840 million loss |
| Net loss allocable to common stockholders | $97,000, versus $13.171 million | $4.140 million, versus $11.180 million |
| Operating cash flow | Not provided for the quarter | -$5.645 million, versus -$5.144 million |
The large year-over-year improvement in reported net results chiefly reflects derivative fair-value changes and gains from negotiated or written-off payables, rather than improved operating profitability. No company-wide profit margin is reported; MuGard U.S. sales were $82,000 in the quarter and $138,000 year to date, while related product costs were $454,000 and $812,000, respectively.
- At September 30, cash and cash equivalents were $1.348 million, versus $7.033 million at December 31, 2010; total assets were $2.220 million.
- Working capital deficit was $12.581 million, up from $6.136 million at year-end. Total liabilities were $25.687 million; stockholders’ deficit was $23.467 million.
- A $5.5 million convertible note was outstanding. The balance sheet classified it as current; the filing describes a restructuring that split repayment and extended part of the note.
- Preferred dividends payable were $5.966 million, and accrued liquidated damages related to preferred-stock registration obligations were $857,000.
- Management reported a net cash burn rate of approximately $697,000 per month for the first nine months. Cash at November 11, 2011 was reported as $5.813 million, after a November 10 equity-and-warrant financing that raised approximately $5.39 million gross.
Changes, outlook, and material risks
- Revenue increased from a low base, including $849,000 of previously deferred license fees recognized after Access regained its ProLindac and MuGard licenses from its former Korean partner. MuGard U.S. sales began in late 2010; European royalties also increased modestly.
- Nine-month R&D spending rose $525,000, principally from clinical development and staffing. Total operating expenses increased $1.315 million.
- Management expected available resources, MuGard revenue, and anticipated license receipts to fund the then-current operating level into the third quarter of 2012, but stated that additional funds would be needed within 12 months and that capital was insufficient for long-term goals. Failure to secure financing or licensing arrangements could threaten the company’s ability to continue as a going concern.
- The November financing sold approximately 3.71 million common shares and warrants for $1.45 per unit, with warrants exercisable at $1.67 and $2.00. It provided near-term cash but diluted existing holders and added potential future dilution.
- MuGard reimbursement coverage had expanded across multiple U.S. payer networks. The company anticipated Chinese marketing approval in the second half of 2011; the filing does not establish that approval was obtained.
- Clinical, regulatory, commercialization, partner-dependence, financing, and future revenue uncertainties remain. The filing notes the prior auditor’s going-concern doubt and warns that results to date do not assure future profitability.
- Disclosure controls were not effective at September 30 because a previously reported material weakness—insufficient accounting staffing, segregation of duties, and review of the CFO’s financial reporting work—remained unremediated. Management said it did not believe the weakness affected current-period financial statement accuracy.
Important facts for investors to verify
- Confirm the issuer: the filing names Access Pharmaceuticals, Inc., whereas the request metadata names Abeona Therapeutics Inc.
- Confirm the note’s repayment schedule: the filing cites differing November 16 and November 17, 2011 due dates in separate passages, and describes a $2.75 million payment tied to the financing or December 1, with the remaining amount extended to September 2012.
- Review the November 10 financing’s final proceeds, share and warrant terms, and resulting dilution, and confirm the reported November cash balance.
- Assess cash runway against actual burn, sales, and license receipts; the stated runway into Q3 2012 depends on assumptions and additional financing remains necessary.
- Track MuGard payer uptake and China regulatory status, and clinical progress for ProLindac and Thiarabine.
- Review the preferred-stock dividend and registration-damages obligations and whether the material weakness in internal controls is remediated.